-
Geneseeq and MGI Tech Form Global Partnership for Oncology Solutions
•
Geneseeq Technology Inc., a genetic cancer testing service provider operating in Canada and China, has entered into a global partnership with China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114). The collaboration leverages MGI’s DNBSEQ gene sequencing platform to conduct in-depth cooperation in clinical basic research, product regulatory filing…
-
Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt
•
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection by the Ministry of Health of Egypt for its Tongboli, a biosimilar version of Novo Nordisk’s GLP-1 receptor agonist Victoza (liraglutide), is well underway in the country. Product BackgroundTongboli, the Victoza knockoff, received marketing approval…
-
United Laboratories’ UBT251 Receives FDA Green Light for Phase II CKD Study
•
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that it has received approval from the US Food and Drug Administration (FDA) to assess its Category 1 drug UBT251 in a Phase II study for the treatment of chronic kidney disease (CKD). Drug ProfileUBT251 is a triple agonist targeting…
-
CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors
•
China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase I study for its CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in Australia. No infusion reactions or other adverse events were observed, marking a promising start to the clinical evaluation of the drug. Drug ProfileCS2009, an…
-
AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal
•
US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the obesity treatment field through a licensing agreement with Denmark-based Gubra A/S (CPH: GUBRA). AbbVie has secured exclusive global development and commercialization rights to GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.…
-
Zeiss Group’s VISUMAX 800 with SMILE pro Software Approved by China’s NMPA
•
Germany-based Zeiss Group, a specialist in optical systems and optoelectronic product manufacturing, announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its new-generation femtosecond laser system VISUMAX 800 with the innovative minimally invasive surgery SMILE pro software. Product HighlightsThe addition of SMILE pro software…
-
Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials
•
Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its investigational drug LAE120 in advanced solid tumors. The drug, a selective USP1 allosteric inhibitor, has a unique chemical structure that differentiates it from other USP1…
-
SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study
•
SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China, announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its SNK-2726. The angiotensinogen (AGT)-targeted small nucleic acid (siRNA) drug is expected to…
-
Omron Healthcare and China Jo-Jo Drugstores Launch Atrial Fibrillation Screening Zone
•
A joint effort between Japan-based Omron Healthcare and China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD), a large open-shelf affordable pharmacy headquartered in Hangzhou, the atrial fibrillation (AF) risk screening zone became operational late last week. The initiative aims to help the public better identify the risk of atrial fibrillation and raise…
-
WORK Medical and Chartwell Med Partner on Investment Tools for Healthcare Projects
•
WORK Medical Technology Group Ltd (NASDAQ: WOK), a medical consumables company based in Hangzhou, has entered into a strategic partnership with Shanghai Chartwell Medical Science & Technology Co., Ltd. The collaboration aims to establish investment tools that integrate industrial and financial resources, facilitate capital collaboration, and drive major project investments.…
-
Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda
•
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory study for its IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion protein. The trial compares IBI363 monotherapy with Keytruda (pembrolizumab) in patients with unresectable locally advanced or metastatic mucosal or acral melanoma who have not…
-
Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment
•
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its finotonlimab. The approval allows the use of the programmed-death 1 (PD-1) monoclonal antibody (mAb) in combination with Anbeizhu, Sinocelltech’s biosimilar version of Roche’s Avastin (bevacizumab), for the…
-
Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline
•
Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB 150 million (USD 21 million) in a new financing round. The round was led by Bayland Capital and included contributions from AstraZeneca-CICC Health Industry Investment Fund, Growth Investment, Panlin Capital, and returning investor Sequoia Capital.…
-
Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics
•
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with Eli Lilly & Co. (NYSE: LLY). The alliance aims to discover, develop, and commercialize molecular glue therapeutics in oncology. Collaboration DetailsSpecifically, Magnet’s TrueGlue discovery platform will be utilized to identify molecular glues capable of inducing…
-
AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study
•
AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase III WAYPOINT study for their co-developed drug Tezspire (tezepelumab). Tezspire is a thymic stromal lymphopoietin (TSLP) – targeted monoclonal antibody (mAb) that has been approved for severe asthma in over 60 countries worldwide. Study ResultsThe…
-
Baidu Health Partners with Jolly Pharma to Boost Digital Drug Marketing
•
Baidu Health, an internet giant, has entered into a partnership with Zhejiang Jolly Pharmaceutical Co., Ltd. Under the agreement, Baidu will leverage its strengths in AI and its internet medicine platform to drive digital marketing innovation for Jolly Pharma’s Bailing capsules and other drugs. The initial focus will be on…
-
Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules
•
China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE) late last week, taking advantage of the Chapter 18A rules to list as a pre-profit biotech company. Morgan Stanley, Jefferies Financial, and CITIC Securities act as its co-sponsors. Company Overview and PipelineSince…
-
CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer
•
CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy, Satricabtagene autoleucel (CT041), has been awarded Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation of the National Medical Products Administration (NMPA). The targeted indication is Claudin18.2-positive advanced gastric / gastroesophageal junction cancer (G…
-
Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio
•
Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing in the Hong Kong Stock Exchange, with the unit price and other details not yet disclosed. Product PortfolioHuge Dental boasts a diverse product portfolio covering oral clinical products, dental technician products, and oral digital products.…
-
Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion
•
Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure, has reportedly raised nearly USD 100 million in a Series C financing round. The funding was led by Qiming Venture Partners and Lilly Asia Ventures, with contributions from returning investors OrbiMed and Gaorong Capital. Company…
